Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Bionor Pharma ASA - Mandatory notification of trade - Lars Høie

Bionor Pharma ASA
Posted on: 28 Sep 16



Lars Høie has on 28 September 2016 sold 25,000,000 shares, disposed of 1,500,000 Subscription Rights and exercised his remaining 96,199,303 Subscription Rights in the rights offering in Bionor Pharma ASA (the "Company"). Following these transactions and issuance of the new shares in the Rights Offering Lars Høie holds 121,453,370 shares, equalling 8.76% of the then issued share capital.

Lars Høie further owns 15,253,370 warrants in the Company. His total holding of shares and warrants equals 9.86% based on the new share capital following registration of the new shares issued in the Rights Offering and equalling 15.88%, based on the registered share capital as of today.

Lars Høie has oversubscribed in the Rights Offering. Allocation of shares is expected on or about 4 October 2016.

This information is subject to the disclosure requirements set out in section 4-3 of the Norwegian Securities Trading Act.


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bionor Pharma ASA via GlobeNewswire

Last updated on: 29/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.